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Conclusion: Preliminary analysis of our data shows encouraging
results with YCF stent in all comer high risk ACS population.
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Twenty patients with unprotected left main disease undergoing
coronary angioplasty between January 2013 and August 2015 have
been studied. Therewere 15males (75%) and 5 females (25%),mean
age 63  11 (35–75 years). Risk factors were Type II Diabetes melli-
tus 7 (35%), Hypertension 8 (40%), Smoking 5 (25%), and Dyslipi-
demia 8 (40%). Clinical presentation was ACS with STEMI 3 (15%),
unstable angina 7 (35%), NSTEMI 8 (40%), and stable angina 2 (10%).
Mean LVEF of the group was 35  5%. Three patients with STEMI
presented in cardiogenic shock.
Right femoral artery was accessed in all patients. Weight adjusted
heparin, aspirin and clopidogrel or prasugrel were used as antic-
oagulants and antiplatelets, respectively. IABP was inserted in the
3 (15%) patients with cardiogenic shock due to acute MI. GP IIb/IIIa
receptor blockers were used in all patients. Distribution of disease
in left main: ostial lesion 3 (15%), diffuse shaft disease 2 (10%),
distal bifurcation 12 (60%), trifurcation 3 (15%). Additional triple
vessel disease was seen in 10 (50%).
Technique: Left main to LAD cross over stenting without ﬁnal
kissing – 8 (40%), two stents strategy: TAP 6 (30%), Cullotte 1
(5%), and DK Crush 1 (5%). In one patient, single stent strategy
with simultaneous kissing balloon angioplasty in Cx was done.
Proximal optimizationwas done in all patients. Ostial stentingwas
done in 3 (15%) patients. Procedural success was achieved in all
patients. All patients received DES. 15 patients (75%) received
indigenous Yukon choice ﬂex (Biodegradable polymer) stent, 3
(15%) received Medtronic Endeavor stent and 2 (10%) patients
received Xience stent (Abott). Mean stent diameter in left main
was 4.0  0.53 mm. Mean number of stents per patient was 1.5. In-
hospital mortality occurred in 3 (15%) patients who were in cardio-
genic shock. There was no other MACE or bleeding during hospi-
talization. Patients were followed clinically or telephonically for a
mean duration of 15  6mo (range 4–20mo). Therewere no further
signiﬁcant events during follow-up.
Conclusion: In appropriately selected patients, PCI of unprotected
leftmain gives gratifying results. The performance of Yukon choice
ﬂex (indigenous) stent has been satisfactory. Mortality remains
high in AMI with cardiogenic shock.
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Background: Contrast induced nephropathy (CIN) is a known
complication following coronary angiography and angioplasty.
Rising creatinine levels after coronary procedures is strongly asso-
ciated with poor clinical outcomes. However in clinical practice
there are situations where coronary procedures are necessary for
patients with pre-existing renal dysfunction. There are some clin-
ical suggestion that trimetazidine (TMZ), an anti-ischemic drug,
may prevent CIN.
Methods: To evaluate the efﬁcacy of trimetazidine in the preven-
tion of CIN in patients with pre-existing renal dysfunction under-
going coronary angiography/angioplasty. It was a prospective
single blind randomized trial where 2 groups of patients of class
III angina with serum creatinine values exceeding 1.5 mg/dl were
selected. One group (group A) was administered intravenous (IV)
saline (0.9%) infusion at a rate of 1 ml/kg of body weight for 24 h
starting 12 h before the procedure while the other group (group B)
received 35 mg twice daily of trimetazidine controlled release (CR)
tablet by mouth for 72 h starting 48 h before the procedure in
addition to IV saline infusion like the ﬁrst group. Baseline serum
creatinine was done 24 h before the procedure for enrolment.
Subsequent creatinine values were obtained 1 h before, and 1, 2,
and 7 days after the procedure.
Results: Over a period of 12months fromApril 1, 2014 till March 31,
2015, 140 patients were included in this study. There were 98 male
patients. Mean age was 67  14 years. Forty eight percent had
diabetes, while 34% were hypertensive and 28% were smokers.
Mean serum creatinine was 1.82  0.44 mg/dl. There were 70
patients in group A, who received only saline infusion and remain-
ing 70 were in group B who had both IV saline and oral trimeta-
zidine CR. Age, sex, risk factors, and clinical symptoms were
properly matched in either group. In all nonionic contrast (Iodix-
anol) was used. One day after angiography/angioplasty there was
no signiﬁcant change of serum creatinine in either group. However
on day 2 post-procedure serum creatinine dropped by mean 8.2%
in group A and 9.5% in group B. The difference was not statistically
signiﬁcant. After 7 days of the procedure mean drop of creatinine
was 8.8% in group A and 12.6% in group B. Reduction of serum
creatinine after 7 days of angiography/angioplasty by TMZ therapy
was statistically signiﬁcant.
Conclusions: The addition of trimetazidine to normal saline sig-
niﬁcantly decreased the incidence of CIN in patients undergoing
coronary angiography/angioplasty. In conclusion, trimetazidine
could be considered as a potential tool for prevention of CIN in
patients with renal dysfunction.
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Background: Although conventional 60 mg prasugrel allows for
rapid and potent platelet inhibition within 30 min after loading
dose, the efﬁcacy and safety of lower doses of prasugrel in Indian
patients has not yet been investigated.
Objective: The study sought to compare the efﬁcacy of a lower
loading dose of prasugrel with conventional loading dose of pra-
sugrel in Indian patients.
Material andmethods: 332 Indian patients undergoing elective PCI
were enrolled in the study. Participants were randomly adminis-
tered loading doses of prasugrel 60 mg (group A, n = 166) or 30 mg
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